🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Non-Center Involving Diabetic Macular Edema Progression in Early Postoperative Period After Phacoemulsification

Recruitingn/aAges 18 Years - anyAllAin Shams University
NCT07038967 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate the progression of non-center-involving diabetic macular edema in the early postoperative period following phacoemulsification.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥18 years. * Both sexes. * Patients with Grade I - Grade II nuclear cataract and non-center-involving diabetic macular edema (NCIDME). Exclusion Criteria: * Traumatic cataract. * Severe Non-Proliferative/ Proliferative Diabetic Retinopathy. * Marked Asymmetry of retinopathy between both eyes. * Mature senile cataract or severe lens opacity. * Potentiality to have Phacotrabeculectomy surgery. * Complications during or after the surgery.
💊

What it tests

  • Coloured photography
  • Fluorescein angiography
  • Optical coherence tomography
📍

Where

1 site
Ain Shams University
Cairo, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy